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Abstract 
Intracerebroventricular (i.c.v.) injection of streptozotocin has been introduced as a means to inhibit glucose utilization in the 
rat brain, and to induce changes in neurotransmitter systems and behavior which resemble those seen in Alzheimer's disease. In 
this study, enzyme activities previously investigated in Alzheimer's disease (peptidases, dehydrogenases and acetyltransferases) 
were measured in the septum and hippocampus of control and streptozotocin-treated rats. Streptozotocin-treated rats receiving 
acetyl-L-carnitine were also included in the experiments, to assess possible neuroprotective effects of this substance. All enzyme 
activities in the septum were affected by streptozotocin, with the exception of choline acetyltransferase activity. By contrast, 
choline acetyltransferase activity was the only enzyme activity affected in the hippocampus. The weight of the septum was 
reduced in streptozotocin-treated animals. These findings indicate that i.c.v, injection of streptozotocin causes septal damage and 
enzymatic changes that do not closely resemble those seen in Alzheimer's disease, which are more specific. Acetyl-L-carnitine 
partly prevented this damage, as reflected by an attenuation of the streptozotocin-induced decrease in hippocampal choline 
acetyltransferase activity. This finding indicates that streptozotocin-treated rats may be valuable to test possible neuroprotective 
effects of drugs. 
Keywords: Streptozotocin; Acetyl-L-carnitine; Brain; Alzheimer's disease; Oxidative stress 
1. Introduct ion 
Recently, Nitsch and Hoyer (1991) introduced in- 
tracerebroventricular (i.c.v.) injection of streptozotocin 
as a means to reduce brain glucose utilization. Besides 
a reduced glucose utilization after i.c.v, injection of 
streptozotocin, cholinergic and monoaminergic deficits 
and behavioral impairments have been observed (Ding 
et al., 1992; Hellweg et al., 1992; Blokland and Jolles, 
1993, 1994). These deficits have been suggested to 
resemble those of Alzheimer's disease and, therefore, 
steptozotocin treatment was assumed to be of rele- 
vance to investigate pathogenetic changes involved in 
Alzheimer's disease (Nitsch et al., 1989; Blokland and 
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Jolles, 1993; Plaschke and Hoyer, 1993). The mecha- 
nism through which streptozotocin causes its effects on 
the brain has not been investigated as yet. Hoyer and 
collaborators speculated that its action on the central 
nervous system might be similar to its peripheral ac- 
tion, i.e. the destruction of insulin-secreting cells or 
interference with the insulin receptor system (Nitsch et 
al., 1989; Nitsch and Hoyer, 1991; Plaschke and Hoyer, 
1993). Systemic administration of streptozotocin is used 
to induce diabetes mellitus in experimental animals 
(Rakieten et al., 1963). Pancreatic /3-cells are selec- 
tively destroyed by streptozotocin (Rakieten et al., 
1963), although the selective vulnerability of these cells 
to streptozotocin is not entirely understood. Several 
studies have demonstrated that inhibitors of poly-ADP 
ribosylation, which is stimulated by single-strand DNA 
breaks, decrease the effect of streptozotocin on pan- 
creatic fl-cells (e.g. Dulin and Wyse, 1969; Bolaffi et 
al., 1987). This suggests that streptozotocin causes DNA 
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damage, which is in accordance with the finding that 
streptozotocin generates DNA-damaging free radicals 
in cultures of pancreatic islets (Takasu et al., 1991). 
The present study addresses the question whether 
changes in enzyme activities as observed in Alzheimer's 
disease are also observed after i.c.v, injection of strep- 
tozotocin. Thus, the possible relevance of the strepto- 
zotocin-treated rat as a model for Alzheimer's disease 
was studied. Several enzyme activities previously stud- 
ied in Alzheimer's disease (Davies, 1979; Kalaria and 
Harik, 1992; Mastrogiacomo et al., 1993; Terwel et al., 
1992, 1994) were measured in the septum and hip- 
pocampus three weeks after i.c.v, injection of strepto- 
zotocin or saline. The enzyme activities measured in 
the studies were those of prolyl endopeptidase, a-keto- 
glutarate dehydrogenase, carnitine acetyltransferase 
and choline acetyltransferase, which are affected in 
Alzheimer's disease, and those of aminopeptidase and 
glutamate dehydrogenase, which are not affected in 
Alzheimer's disease. Choline acetyltransferase activity 
was used as a marker of cholinergic neurons, which die 
or shrink in Alzheimer's disease. The other enzyme 
activities are of a ubiquitous nature. The present study 
also addresses the question whether in the brain a-ke- 
toglutarate dehydrogenase is selectively affected by 
streptozotocin as compared to glutamate dehydroge- 
nase, which has been shown to be the case in pancre- 
atic/3-cells (Rasschaert et al., 1992). 
L-Carnitine and its acetylated form, acetyl-L-carni- 
tine, are endogenous substances in various organs, 
including the brain (Bieber, 1988). L-Carnitine has a 
role in the B-oxidation by mitochondria of organs such 
as liver and muscle. This role of L-carnitine is of minor 
importance in the brain, since the brain almost exclu- 
sively depends on the oxidation of glucose to meet its 
energy demands. However, L-carnitine and acetyl-L- 
carnitine may be involved in the regulation of metabolic 
pathways in the brain (and other organs) by having an 
influence on the regeneration of CoASH and modula- 
tion of the level of acetyl-CoASH in the mitochondria. 
In addition, acetyl-L-carnitine may have a role as a 
precursor of acetylcholine, by providing the acetyl moi- 
ety for acetylcholine synthesis (White and Scates, 1990). 
Chronic treatment with acetyl-L-carnitine has been 
shown to prevent impaired neuronal functioning in 
aged rats, both at the neurochemical level (Napoleone 
et al., 1990; Patacchioli et al. 1989; Taglialatela et al. 
1994) and at the behavioral level (Barnes et al., 1990; 
Caprioli et al, 1990; Ghirardi et a1.,1988, 1992). More- 
over, it has been found that chronic treatment with 
acetyl-L-carnitine increases cholinergic functioning af- 
ter fimbria-fornix transection (Piovesan et al. 1994), 
and attenuates behavioral deficits induced by i.c.v. 
treatment with cyanide (Blokland et al., 1993) or strep- 
tozotocin (Prickaerts et al., 1995). However, no uni- 
form explanation has been offered to explain these 
neuroprotective effects of acetyl-L-carnitine. As neu- 
ronal functioning may be affected after streptozotocin 
treatment, the effects of chronic treatment with acetyl- 
L-carnitine on the enzyme activities mentioned were 
also evaluated in the streptozotocin-treated rats. 
2. Materials and methods 
2.1. Animals 
For the first experiment 23 male Lewis rats of 18 
months of age were used. The rats were divided over 
three groups of seven to nine animals. One group of 
rats was given acetyl-L-carnitine (75 mg/kg per day) in 
the drinking fluid (0.1% saccharine). After 2 weeks on 
acetyl-L-carnitine the rats were anesthetized with pen- 
tobarbital (60 mg/kg, i.p.) and placed in a stereotaxic 
frame. A skin incision was made to free the skull and 
two holes were drilled above the lateral ventricles. The 
animals were given an injection of 2 /xl of streptozo- 
tocin solution in each lateral ventricle (total dose 1.5 
mg/kg body weight). The stereotaxic coordinates were 
-0.8 mm anterior, 1.55 mm lateral and -3 .8  mm 
ventral from bregma (Paxinos and Watson, 1988). 
Streptozotocin was dissolved in saline just prior to 
injection. Another group of rats was not given acetyl- 
L-carnitine in the drinking fluid, but received injections 
of streptozotocin only. A third group of animals re- 
ceived injections with saline. 3 weeks after injection the 
animals were decapitated and the brains were removed 
from the skull in a cold room for dissection of the 
septum and hippocampus. For the second experiment 
16 rats were used, divided over two groups of eight 
animals. The rats were treated in the same manner as 
in the first experiment, except that none of the rats was 
treated with acetyl-L-carnitine. 
2.2. Enzyme assays 
Brain tissues were homogenized in 19 volumes of 50 
mM sodium phosphate (pH 7.4). Part of the ho- 
mogenates was centrifuged at high speed to obtain 
particle-free fractions. In both experiments prolyl en- 
dopeptidase, aminopeptidase and choline acetyltrans- 
ferase activities were determined. In addition, carnitine 
acetyltransferase activity was determined in the first 
experiment and o~-ketoglutarate dehydrogenase, and 
glutamate dehydrogenase activities in the second ex- 
periment. All enzyme activities were not determined in 
a single experiment because of insufficient material. 
2.2.1. Prolyl endopeptidase 
Prolyl endopeptidase activity was determined spec- 
trophotometrically with N-succinyl-Gly-Pro-Leu-Gly- 
Pro-7-amido-4-methylcoumarin as substrate. The sub- 
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strate (0.1 mM) was incubated with 10/zl cytosol in 200 
/xl of a buffer consisting of 50 mM Tris (pH 7.4), 1 mM 
D T F  and 1 mM EDTA,  at 37°C. After  1 h of incuba- 
tion the reaction was stopped by the addition of 0.3 ml 
1 M acetic acid. Extinction was measured at a wave- 
length of 373 nm. 
2.2.2. Aminopeptidase 
Aminopept idase activity was measured with alanine 
p-nitroanilide as substral~e. The substrate (0.5 mM) was 
incubated with 10/xl cytosol in 200/~1 50 mM Tris (pH 
7.4) at 37°C. After  30 rain of incubation the reaction 
was stopped by the addition of 0.3 ml ethanol. Extinc- 
tion was measured at a wavelength of 410 nm. 
2.3. Statistics 
Data  of the first experiment were subjected to a 
one-way analysis of variance with t reatment  as the 
dependent  variable. Trea tment  effects between the 
three experimental  groups were evaluated in more 
detail by using Student-Newman-Keuls test. Trea tment  
effects in the second experiment were assessed by 
using Student 's  t-test. Relationships between measures 
were assessed by calculating Pearson's  correlation coef- 
ficient (R). 
3. Results 
2.2.3. a-Ketoglutarate de,hydrogenase 
a-Ketoglutara te  dehydrogenase activity was deter- 
mined in the homogenates  according to the procedure 
of Lai and Cooper  (1986). 
2.2.4. Glutamate dehydrogenase 
Glutamate  dehydrogenase activity was determined 
spectrophotometrically. 'The reaction mixture consisted 
of 50 mM Tris (pH 8.0), 2.5 mM EDTA,  100 mM 
ammonium acetate, 0.2 mM NADH,  1 mM ADP,  7 
mM a-ketoglutarate,  and 20 /xl 2% homogenate  in a 
final volume of 1 ml. The reaction, at ambient temper-  
ature, was started by the addition of a-ketoglutarate.  
The disappearance of N A D H  was monitored at a 
wavelength of 340 nm. 1~o calculate enzyme activity a 
correction was made for the change in extinction in the 
absence of a-ketoglutarate.  
2.2.5. Choline acetyltranfferase and carnitine acetyltrans- 
ferase 
Choline acetyltransferase activity was measured in 
the homogenates  according to the method of Fonnum 
(1975). The method for the determination of carnitine 
acetyltransferase activi~¢ was identical to the method 
for the determination of choline acetyltransferase ac- 
tivity, except that L-carnitine hydrochloride was used as 
substrate instead of choline chloride and the reaction 
was stopped with 10 mlVl phosphate  (pH 3.0) instead of 
14% trichloroacetic acid. 
3.1. Experiment 1 
Septum weights + S.E.M. (mg) were 17.0 + 1.0, 9.2 
+ 1.3, and 11.9 + 1.9 in the control, the streptozotocin- 
injected and the acetyl-L-carnitine-treated, streptozo- 
tocin-injected rats, respectively. The weight of the sep- 
tum was reduced after injection of streptozotocin in 
both the animals t reated with acetyl-L-carnitine and 
the untreated animals ( P  < 0.01). The weight of the 
hippocampus was unchanged (data not shown). 
The enzyme activities in the septum of the saline-in- 
jected, the streptozotocin-injected and the acetyl-L- 
carnitine-treated, streptozotocin-injected rats are given 
in Table 1. The three experimental groups differed in 
septal  prolyl endopep t idase  activity ( P  < 0.05), 
aminopeptidase activity ( P  < 0.05) and carnitine acetyl- 
transferase activity ( P  < 0.01). Septal choline acetyl- 
transferase activity only tended to be different between 
the groups (0.05 < P < 0.1). Post hoc analysis revealed 
that prolyl endopeptidase,  aminopeptidase and carni- 
tine acetyltransferase activities were reduced in the 
septum of the streptozotocin-injected animals, whereas 
choline acetyltransferase activity was not changed. 
Trea tment  with acetyl-L-carnitine did not prevent pro- 
lyl endopeptidase and carnitine acetyltransferase activ- 
ities from being reduced. Aminopept idase  activity was 
spared by t reatment  with acetyl-L-carnitine. However, 
septal choline acetyltransferase activity of the acetyl-L- 
carnitine-treated, streptozotocin-injected rats was even 
Table 1 
Enzyme activities in the septum of saline-injected, streptozotocin-injected and acetyl-L-carnitine-treated, streptozotocin-injected rats of experi- 
ment 1 
Enzyme activity Control 
(nmol • h - i. mg- 1 protein) 
Prolyl endopeptidase 72 + 5 a 
Aminopeptidase 568 + 24 a 
Carnitine acetyltransferase 1219 + 31 a 
Choline acetyltransferase 100 + 9 a 
Streptozotocin Acetyl-L-carnitine, 
streptozotocin 
46+ 5b 56+ 6a'b 
486 + 17 b 564 + 24 a 
858 + 70 b 949 + 71 b 
110+ 7a'b 135+13b 
Data represent means + S.E.M. Means of enzyme activities with the same superscript are not different (Student-Newman-Keuls test, P < 0.05). 
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Table 2 
Enzyme activities in the hippocampus of saline-injected, streptozotocin-injected and acetyl-L-carnitine-treated, streptozotocin-injected rats of 
experiment 1 
Enzyme activity Control Streptozotocin Acetyl-L-carnitine, 
(nmol • h - 1 . mg- ~ protein) streptozotocin 
Prolyl endopeptidase 125 _ 5 a 123 ± 7 a 127 ± 4 a 
Aminopeptidase 569 _+ 28 a 535 ± 25 a 621 _+ 41 a 
Carnitine acetyltransferase 854 + 27 a 786 +_ 35 a 857 ± 21 a 
Choline acetyltransferase 117 ± 3 a 44 ± 13 b 84 ± 16 a 
Data represent means ± S.E.M. Means of enzyme activities with the same superscript are not different (Student-Newman-Keuls test, P < 0.05). 
Table 3 
Pearson's correlation coefficients for data from experiment 1 on 
septum weight and enzyme activities 
Enzyme activity R P 
Prolyl endopeptidase 0.838 < 0.001 
Aminopeptidase 0.594 < 0.01 
Carnitine acetyltransferase 0.754 < 0.001 
Choline acetyltransferase -0.272 > 0.05 
Table 4 
Enzyme activities in the septum of saline-injected and streptozo- 
tocin-injected rats from experiment 2 
Enzyme activity Control Streptozotocin 
(nmol • h-  1. mg- 1 protein) 
Prolyl endopeptidase 66 + 3 35 + 6 * * 
Aminopeptidase 567 + 12 418 ± 29 * * 
a-Ketoglutarate dehydrogenase 545 + 33 306 + 27 * * 
Glutamate dehydrogenase 5938 + 218 2602 + 149 * * 
Data represent means+ S.E.M. Asterisks indicate differences with 
respect to control (t-test, P < 0.001). 
Table 5 
Enzyme activities in the hippocampus of saline-injected and strepto- 
zotocin-injected rats from experiment 2 
Enzyme activity Control Streptozotocin 
(nmol - h-  1. mg- i protein) 
Prolyl endopeptidase 137+ 10 128+ 8 
Aminopeptidase 682___ 48 607 + 26 
a-Ketoglutarate dehydrogenase 615 -t- 45 650_+ 49 
Glutamate dehydrogenase 8106 + 308 8065 + 279 
Choline acetyltransferase 92 + 2 39 + 13 * 
Data represent means + S.E.M. Asterisk indicates a difference with 
respect to control (t-test, P < 0.01). 
Table 6 
Pearson's correlation coefficients for data from experiment 2 on 
septum weight and enzyme activities 
Enzyme activity R P 
Prolyl endopeptidase 0.977 < 0.001 
Aminopeptidase 0.901 < 0.001 
tr-Ketoglutarate dehydrogenase 0.691 < 0.01 
Glutamate dehydrogenase 0.845 < 0.001 
higher than  that  of the sal ine-injected rats. In  the 
h ippocampus  of all exper imental  groups prolyl en- 
dopeptidase,  aminopept idase ,  and  carni t ine  acetyl- 
t ransferase activities were unaffected (see Table  2, P 
values > 0.05), whereas  choline acetyltransferase activ- 
ity was affected ( P  < 0.01). Post hoc analysis showed 
that  t r ea tmen t  with acetyl-L-carnitine a t t enua ted  the 
decrease in choline acetyltransferase activity in the 
h ippocampus  elicited by streptozotocin.  
High correlat ions were found be tween  septum 
weight and  enzyme activities, except choline acetyl- 
t ransferase activity (see Table  3). The  correlat ion be- 
tween choline acetyltransferase activity in the sep tum 
and that  in the h ippocampus  was poor  (R = - 0 .093 ,  P 
> 0.05), bu t  the correla t ion be tween  sep tum weight 
and  choline acetyltransferase activity in the hippocam- 
pus was high (R = 0.832, P < 0.001). 
3.2. Experiment 2 
Septum weights + S.E.M. (mg) were 17.2 + 0.5 and  
7.9 + 1.5 in the control  and  the s t reptozotocin- injected 
rats, respectively. The  weight of the septum was re- 
duced after inject ion of s t reptozotocin ( P  < 0.001). The  
weight of the h ippocampus  was unaffected (data not  
shown). 
Prolyl endopep t idase ,  aminopep t idase ,  a -ke to -  
glutarate  dehydrogenase,  and  g lu tamate  dehydroge- 
nase activities in the sep tum were reduced after  injec- 
t ion of s t reptozotocin (see Table  4), whereas in the 
h ippocampus  these enzyme activities were not  affected 
by streptozotocin.  However,  choline acetyltransferase 
activity in the h ippocampus  of the s t reptozotocin-in-  
jected rats was reduced compared  with that  of the 
control  animals  (see Table  5). 
High correlat ions were found be tween  sep tum 
weight and enzyme activities (see Table  6). The  corre- 
lat ion be tween  sep tum weight and  choline acetyltrans- 
ferase activity in the h ippocampus  was high (R = 
0.917, P < 0.001). 
4. Discussion 
In  the present  study the effects of s t reptozotocin on  
enzyme activities in the sep tum and  h ippocampus  of 
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control rats and of rats treated with acetyl-L-carnitine 
were studied. Streptozotocin affected enzyme activities 
in the septum rather indiscriminately, except choline 
acetyltransferase activity, whereas it affected only 
choline acetyltransferase, activity in the hippocampus. 
Acetyl-L-carnitine did not spare all the enzyme activi- 
ties in the septum, but seemed to preserve the cholin- 
ergic function in the hippocampus to some extent. The 
general effect of streptozotocin on enzyme activities in 
the septum contrasts with its reportedly selective ef- 
fects on enzyme activities in pancreatic /3-cells (Ras- 
schaert et al., 1992). This difference might be explained 
by the possibility that streptozotocin may have caused 
cell death in the septum, whereas enzyme activities in 
pancreatic fl-cells have been measured in cells surviv- 
ing the insult by streptozotocin. 
The above findings suggest that cholinergic neurons 
in the septum were relatively spared from the degener- 
ative effects of streptozotocin. This does not necessar- 
ily mean that cholinergic neurons are less vulnerable to 
streptozotocin than other cells, since many of the non- 
cholinergic cells in the septum are closer to the injec- 
tion site than the cholinergic neurons. The relative 
sparing of the cholinergic neurons may have been 
enhanced by acetyl-L-carnitine. Histological and im- 
munocytochemical studies are in progress to assess 
which brain structures are affected by streptozotocin. 
Specific choline acetyltransferase activity in the sep- 
tum was unaffected by streptozotocin, whereas specific 
choline acetyltransferase activity in the hippocampus 
was reduced. This seems surprising, since the hip- 
pocampus receives a cholinergic input from the sep- 
tum. However, the septum weight was reduced, whereas 
the hippocampus weight was unaltered, so that in both 
structures total choline acetyltransferase activity was 
reduced. In addition, total choline acetyltransferase 
activities in these two structures were strongly corre- 
lated (R = 0.751, P < 0.001). Therefore, the reduced 
choline acetyltransferase activity in the hippocampus 
can be explained by an effect of streptozotocin at the 
level of the septum. 
Interestingly, choline acetyltransferase activity cor- 
related highly with carrfitine acetyltransferase activity 
in the hippocampus (R = 0.712, P < 0.001), although 
this latter activity was not significantly reduced after 
injection of streptozotocin. In addition, hippocampal 
carnitine acetyltransferase activity correlated both with 
septal carnitine acetyltransferase activity (R = 0.499, P 
< 0.05) and with septum weight (R = 0.607, P < 0.01). 
These correlations suggest that carnitine acetyltrans- 
ferase may be linked to the septohippocampal path- 
way. This may have to do with the possibility that the 
enzyme is preferentially located in cholinergic nerve 
endings. This possibiliv.¢ is in accordance with some 
previous findings. First, lesion of the habenulointerpe- 
duncular tract has been shown to result in reduced 
activity of both carnitine acetyltransferase and choline 
acetyltransferase in the interpeduncular nucleus (Sterri 
and Fonnum, 1980). Second, it has been reported that 
nerve growth factor (NGF) increases both carnitine 
acetyltransferase and choline acetyltransferase activi- 
ties in PC12 cells (White and Scates, 1991). Moreover, 
these results suggest that preferential localization of 
carnitine acetyltransferase in cholinergic terminals is a 
general phenomenon. 
The fact that enzyme activities were affected rather 
indiscriminately in the septum together with a reduced 
weight of the septum suggests that streptozotocin acts 
as a non-selective neurotoxin near the site of injection. 
Hoyer and collaborators, who used the same dose of 
streptozotocin as used in this study, found rather 
widespread effects of streptozotocin on energy 
metabolism and neurotransmitter systems and ascribed 
these effects to a possible interference of streptozo- 
tocin with the action of insulin in the brain. However, 
our finding of septal degeneration is not in line with 
such a specific effect of streptozotocin on the action of 
insulin. The destruction of septal-hippocampal and 
septal-cortical connections may have contributed to the 
effects of streptozotocin in locations distant from the 
septum. Therefore, with respect to the mechanism of 
action of streptozotocin an alternative hypothesis may 
be formulated. Since it has been shown that streptozo- 
tocin causes its effects on pancreatic /3-cells by the 
generation Of hydrogen peroxide (Takasu et al., 1991), 
it can be hypothesized that streptozotocin does so in 
the central nervous system as well. 
There is evidence that oxidative stress is important 
in the pathogenesis of Alzheimer's disease and other 
neurodegenerative diseases (reviewed by Olanow, 
1993). This evidence is for the most part indirect, 
consisting of alterations in the accumulation of peroxi- 
dation products in tissues (Andorn et al., 1990; Palmer 
and Burns, 1994) and changes in the activity of en- 
zymes sensitive to changes in redox status (Terwel et 
al., 1992; Morrison et al., 1993). Interestingly, it has 
recently been shown that/3-amyloid peptide increases 
the production of oxygen free radicals by stimulating a 
NADPH oxidase-like activity or by an auto-oxidative 
process (Behl et al., 1994; Goodman et al., 1994). 
However, i.c.v, injection of streptozotocin caused a 
general decline in the enzyme activities determined, 
whereas in Alzheimer's disease some of these enzyme 
activities are reduced and others are not (Terwel et al., 
1992; Mastrogiacomo et al., 1993). The effect of strep- 
tozotocin on the septum may have been too strong to 
mimic what is going on in Alzheimer's disease. In 
addition, the septum may not be the most appropriate 
area to induce Alzheimer's disease-like features, since 
brain areas other than the septum are affected by 
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Alzheimer's disease. Future studies should investigate 
the effects of low doses of streptozotocin in brain areas 
that are affected in Alzheimer's disease. 
Two effects of acetyl-L-carnitine reported in the 
literature may be of relevance to explain the positive 
effects of acetyl-L-carnitine on the septohippocampal 
cholinergic system. Firstly, acetyl-L-carnitine increases 
the binding of NGF to its receptor in aged rat central 
nervous system (Angelucci et al., 1988). Secondly, in 
PC12 cells acetyl-L-carnitine increases the synthesis of 
the NGF receptor (Taglialatela et al., 1992) and the 
subsequent internalization of NGF (Taglialatela et al., 
1991), which is important in the action of NGF. Corre- 
spondingly, it has been found that acetyl-L-carnitine 
increases NGF levels and choline acetyltransferase ac- 
tivity in the central nervous system of fimbria-fornix 
transectioned rats (Piovesan et al., 1994) and aged rats 
(Taglialatela et al., 1994). Finally, the fact that NGF 
plays a role in oxidant homeostasis (Pan and Perez- 
Polo, 1993) strengthens the possibility that NGF is 
involved in the neuroprotective effect, of acetyl-L- 
carnitine against the damaging effects of streptozo- 
tocin. 
In conclusion, i.c.v, injection of streptozotocin causes 
structural damage in the septum. This damage causes 
enzymatic changes that do not closely resemble the 
more specific changes in enzyme activities as observed 
in Alzheimer's disease. Acetyl-L-carnitine partly pre- 
vents this damage, as reflected by an attenuation of the 
streptozotocin-induced decrease in hippocampal 
choline acetyltransferase activity. This finding indicates 
that streptozotocin-treated rats may be valuable to test 
neuroprotective effects of substances. Furthermore, it 
demonstrates that acetyl-L-carnitine has a neuroprotec- 
tive action on cholinergic neurons. However, little is 
known about the neuroprotective effect of acetyl-L- 
carnitine on non-cholinergic neurons. Injection of low 
doses of streptozotocin in brain sites other than the 
septum in combination with assessment of markers of 
specific neuronal populations may be a way to study 
the neuroprotective effects of acetyl-L-carnitine on 
non-cholinergic neurotransmitter systems. 
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